Find the best home for your work
Navigating today’s publishing landscape has become more important than ever, given the rising volume in publication output, the growing number of venues to disseminate your research, and the pressures to publish your research promptly in a reputable journal.
At BMJ Group, we offer a wide selection of high-quality journals across various medical disciplines, making it easier for you to find the perfect match for your research. As an evidence based publisher, our brand can be trusted to provide you with exceptional editorial expertise and the highest standards in peer review and publication ethics.
Explore our journal portfolio
With over 60 reputable journals spanning 30 medical and allied science specialties, you’re sure to find one that aligns with your research.
Browse our collection of journals today and take the next step toward publication.
Real voices, real change
Our newest impact stories show how research in our journals is shaping better patient outcomes and informing healthcare policy. See the difference evidence-based science makes.
How evidence based policy can drive meaningful change
Researchers from the University of Calgary published a paper in 2015 titled “Policy change eliminating body checking in non-elite ice hockey leads to a threefold reduction in injury and concussion risk in 11 and 12 year old players” in the British Journal of Sports Medicine.
How Ugandan research shaped covid-19 treatment
In August 2021, Dr Bruce Kirenga and his team at the Makerere University Lung Institute published a pivotal study in BMJ Open Respiratory Research on the efficacy of convalescent plasma for covid-19 treatment in Uganda. The study’s findings on the limited efficacy of convalescent plasma (CP) helped shape major treatment guidelines.
Helping clinicians manage one of immunotherapy’s most serious risks
Published in 2018 in the Journal for ImmunoTherapy of Cancer, a major review of cytokine release syndrome (CRS) found that, as breakthrough therapies like CAR T cell treatment and bispecific antibodies moved into routine clinical use, they also carried a serious risk of triggering the potentially life-threatening inflammatory reaction.
